Dynamics of viral disease outbreaks: A hundred years (1918/19–2019/20) in retrospect‐Loses, lessons and emerging issues
NI Nii‐Trebi, TS Mughogho, A Abdulai… - Reviews in Medical …, 2023 - Wiley Online Library
Infectious diseases continue to be the leading cause of morbidity and mortality, and a
formidable obstacle to the development and well‐being of people worldwide. Viruses …
formidable obstacle to the development and well‐being of people worldwide. Viruses …
[HTML][HTML] Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis
S Xu, J Li, H Wang, F Wang, Z Yin, Z Wang - BMC medicine, 2023 - Springer
Background The two inactivated SARS-CoV-2 vaccines, CoronaVac and BBIBP-CorV, have
been widely used to control the COVID-19 pandemic. The influence of multiple factors on …
been widely used to control the COVID-19 pandemic. The influence of multiple factors on …
[HTML][HTML] Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination
X Tong, RP McNamara, MJ Avendaño… - Nature …, 2023 - nature.com
Since the emergence of SARS-CoV-2, vaccines targeting COVID-19 have been developed
with unprecedented speed and efficiency. CoronaVac, utilising an inactivated form of the …
with unprecedented speed and efficiency. CoronaVac, utilising an inactivated form of the …
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States
MA Kohli, M Maschio, K Joshi, A Lee… - Journal of Medical …, 2023 - Taylor & Francis
Aims To assess the potential clinical impact and cost-effectiveness of COVID-19 mRNA
vaccines updated for fall 2023 in adults aged≥ 18 years over a 1-year analytic time horizon …
vaccines updated for fall 2023 in adults aged≥ 18 years over a 1-year analytic time horizon …
Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
P Sritipsukho, T Khawcharoenporn… - Emerging Microbes & …, 2023 - Taylor & Francis
The surge in coronavirus disease 2019 (COVID-19) caused by the Omicron variants of the
severe acute respiratory syndrome coronavirus 2 necessitates researches to inform vaccine …
severe acute respiratory syndrome coronavirus 2 necessitates researches to inform vaccine …
Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use …
Background People with substance use disorder have a high risk of SARS-CoV-2 infection
and subsequent poor outcomes. Few studies have evaluated COVID-19 vaccine …
and subsequent poor outcomes. Few studies have evaluated COVID-19 vaccine …
[HTML][HTML] Impact of vaccination against severe COVID-19 in the French population aged 50 years and above: a retrospective population-based study
L Tan-Lhernould, C Tamandjou, G Deschamps… - BMC medicine, 2023 - Springer
Background Given the widespread implementation of COVID-19 vaccination to mitigate the
pandemic from the end of 2020, it is important to retrospectively evaluate its impact, in …
pandemic from the end of 2020, it is important to retrospectively evaluate its impact, in …
Superior boosting of neutralizing titers against Omicron SARS-CoV-2 variants by heterologous SCB-2019 vaccine vs a homologous booster in CoronaVac-primed …
CC Roa Jr, MRA de Los Reyes… - The Journal of …, 2023 - academic.oup.com
Background We compared homologous and heterologous boosting in adults in the
Philippines primed with 2 or 3 doses of CoronaVac, with recombinant protein vaccine, SCB …
Philippines primed with 2 or 3 doses of CoronaVac, with recombinant protein vaccine, SCB …
[HTML][HTML] Bioinformatic analysis and preliminary validation of potential therapeutic targets for COVID-19 infection in asthma patients
Y Li, Y Liu, M Duo, R Wu, T Jiang, P Li, Y Wang… - Cell Communication and …, 2022 - Springer
Background Severe acute respiratory syndrome coronavirus 2 causes coronavirus disease
19 (COVID-19). The number of confirmed cases of COVID-19 is also rapidly increasing …
19 (COVID-19). The number of confirmed cases of COVID-19 is also rapidly increasing …
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
CC Roa Jr, MRA de Los Reyes… - Human Vaccines & …, 2024 - Taylor & Francis
We assessed the non-inferiority of homologous boosting compared with heterologous
boosting with the recombinant protein vaccine, SCB-2019, in adults previously immunized …
boosting with the recombinant protein vaccine, SCB-2019, in adults previously immunized …